The anti-tumor activity of a newly developed Hsp90 inhibitor, NVP-AUY922 (AUY922), against non-small cell lung cancer (NSCLC) was examined. Twenty-one NSCLC cell lines were used, the somatic alterations of which were characterized. Cell proliferation was analyzed using a modified MTS assay. Expression of the client proteins was assessed using Western blotting. The cell cycle was analyzed using flow 
Introduction
Lung cancer is associated with various types of molecular alteration, including epidermal growth factor receptor (EGFR) mutation, K-ras mutation, HER2
amplification and, as recently found, EMK4-ALK gene fusion. [1] [2] [3] Improvements in our understanding of the molecular alterations involved in lung cancer have brought significant advancements in molecular-targeted therapy. [4] Among these alterations, EGFR mutations, which are frequent alterations in lung adenocarcinoma, are a predictive factor for the efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. [1, 2] These EGFR-TKIs have a marked anti-tumor effect on NSCLCs with common EGFR mutations. However, acquired resistance from, for example, a secondary EGFR T790M mutation or MET amplification is a major problem that is responsible for treatment failure. [5] [6] [7] The heat-shock protein 90 (Hsp90) complex is a chaperone protein that facilitates the refolding of unfolded or misfolded proteins. It plays a pivotal role in cancer cell survival, as it stabilizes a large set of proteins, so-called client proteins, many of which are essential for apoptosis, cell-cycle regulation, proliferation, and other characteristic properties of cancer cells. [8, 9] In NSCLC, Hsp90 stabilizes oncogenic proteins such as EGFR, MET, HER2 and AKT. [9, 10] We and some other studies have shown that geldanamycin (GM) and its analogues, the benzoquinone ansamycin class were somewhat disappointing [15] [16] [17] [18] [19] and new potent Hsp90 inhibitors have therefore been pharmacologically designed and synthesized to offer improved efficacy and acceptable toxicity. NVP-AUY922 (AUY922) is one of these newly designed small-molecule Hsp90 inhibitors based on the 4,5-diarylisoxazole scaffold; it has a much higher affinity for Hsp90 than previous GM analogues. [20] AUY922 is bound to the ATP binding site of Hsp90α at the N-terminal domain, and its X-ray crystal structure confirms a crucial network of hydrogen bonding interactions. It exhibits the tightest binding of any small-molecule Hsp90 ligand because the entropy of binding to Hsp90 is almost negligible. Indeed, preclinical data from various types of human cancer have shown an anti-proliferative effect of AUY922, with low nanomolar potency both in vivo and in vitro, with no major adverse effects being observed in mice. [20] [21] [22] [23] [24] In these studies, AUY922 suppressed the client proteins (EGFR, MET, HER2 and AKT)
that participate in the progression of various cancer cells, and AUY922 is considered to 6 be a promising agent for NSCLC. However, to our knowledge, the efficacy of AUY992 has been reported in only one NSCLC cell line (A549) to date, [25] although Phase II clinical trials for patients with advanced NSCLC have recently started.
In this study, we examined the anti-tumor effect of AUY922 against NSCLC cell lines containing several known genetic alterations, including EGFR mutations. PC-9 was provided from Immuno-Biological Laboratories (Takasaki, Gunma, Japan).
Materials and methods

Drugs and cell lines
Gefitinib-resistant PC-9 cell line (RPC-9) were provided from the Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate
School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan. [26] All the cancer cell lines were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum. All cell lines were incubated at 37°C in a humidified atmosphere with 5% CO 2 . AQueous One Solution Reagent were dropped into each well of plates. After the incubation of another 60 minutes, the optical densities (OD) of these samples were directly measured using an Immuno Mini NJ-2300 (Nalge Nunc International, Rochester, NY). A reference wavelength at 490 nm was used to subtract background contributed by excess cell debris, fingerprints and other nonspecific absorbance. The OD of control samples was regarded as 100 and others were compared to the control.
Determination of cell proliferation
Each drug concentration was distributed in 4-replicate wells and each experiment was repeated thrice. The anti-proliferative activity of AUY922 was shown as IC 50 , which is the concentration of the drug required to inhibit cell proliferation by 50%.
Western blot analysis and immunoprecipitation
Protein expression analysis was assessed by Western blotting. The lysate was extracted and 20 µg of total protein were then separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membrane. The membranes were incubated with anti-EGFR, anti-phospho-EGFR (Ty1068), anti-Met (25H2), anti-phospho-Met (3D7, Tyr1234/1235), anti-HER2, anti-phospho-HER2 (Tyr877), anti-Akt, anti-phosphor-Akt (Ser473), anti-p44/42 mitrogen-activated protein kinases (MAPK),
Results
Anti-proliferative effect of AUY922 in NSCLC cell lines
The concentrations of AUY922 at IC 50 in each cell line are shown in Table I and Fig. 1 . The molecular characteristics of NSCLC cell lines are also described ( Table   I ). We also determined the IC 50 value of the SKBR3 breast cancer cell line to validate the IC 50 value determined with our MTS assay by comparing it with published data. [22] Our and previously published IC 50 values were 9.7 + 3.5 nM and 3.3 + 0.9 nM, respectively, suggesting that the IC 50 value measured using our system was not remarkably different from the published data. [22] Thus, in accordance with the 11 published criteria, an IC 50 value of less than 50 nM was regarded as being a sensitive cell line. [22] On the basis of this criteria, 19 of the 21 NSCLC cell lines and two of the five MPM cell lines were classified as being sensitive (p=0.034).
Two cell lines, H1395 and Calu3, were considered to be resistant. H1395
contains a B-raf mutation as a known molecular alteration, while Calu3 has a strong amplification of HER2 and increased copy numbers of EGFR and PIK3CA. However, the H2170 cell line, which also exhibited strong HER2 amplification and an increased copy number of EGFR, was classified as a sensitive cell line (IC 50 = 9.1 + 0.3),
suggesting that amplification of HER2 or EGFR is not the factor that causes resistance to AUY922.
Effects of AUY922 on molecular signature in NSCLC cell lines
Subsequent experiments focused on NSCLC. The effect of AUY922 on protein expression was examined according to concentration and exposure time in three sensitive cell lines (H1975, A549 and H838) and two resistant cell lines (H1395 and Calu3). Cells were harvested 24 hours after drug treatment in a concentration gradient experiment ( Fig. 2 and Supplementary Fig. 1 ). In sensitive cell lines, the depletion of both the total and the phosphorylated client proteins, such as EGFR, MET, HER2, AKT, and Cyclin D1 (CCND1), was observed after treatment with 50 nM of AUY922. Fig. 2 and Supplementary Fig. 1 ).
Suppression of phospho-MAPK (p-MAPK) but not total-MAPK (t-MAPK
For exposure time analysis, each cell line except H1395 was treated with the AUY922 concentration, which was five times as high as each IC 50 . H1395, the IC 50 of which was 850 nM, was exposed to 100 nM of AUY922. Although variation of protein depletion and recovery was observed according to proteins or cell lines, decreased expression of the majority of proteins was observed from 12 to 72 hours ( Fig. 3 and Supplementary Fig. 2 ). Of note, there was no major difference in the pattern of the protein expression profile time course between sensitive cell lines and H1395-resistant cell lines. 
Effects of AUY922 on cell cycle and apoptosis
We analyzed the cell cycle in two sensitive cell lines (H1975 and H838) to examine the impact of AUY922 on cell-cycle distribution, especially induction of apoptosis. Whereas the pattern of cell-cycle distribution after treatment of AUY922 was different between two cell lines, sub-G 0 -G 1 DNA content increased in a time-dependent manner for both cell lines. Cleaved PARP also increased with AUY922 treatment, indicating that AUY922 induced apoptosis in these two cell lines (Fig. 4) .
Discussion
In this study, we found that AUY922 had a strong anti-proliferative effect on In conclusion, our study suggests that AUY922 is a potent candidate for the treatment of the majority of NSCLCs, independent of the major known genetic alterations.
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